[1] |
FERRERAS-ANTOLÍN L, SHARLAND M, WARRIS A. Management of invasive fungal disease in neonates and children[J]. Pediatr Infect Dis J, 2019, 38(6S Suppl 1): S2-S6. |
[2] |
WARRIS A, LEHRNBECHER T, ROILIDES E, et al. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children[J]. Clin Microbiol Infect, 2019, 25(9):1096-1113. |
[3] |
MCCREARY EK, DAVIS MR, NARAYANAN N, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium[J]. Pharmacotherapy. 2023, 43(10): 1043-1050. |
[4] |
中华医学会儿科学分会, 中华儿科杂志编辑委员会. 儿童侵袭性肺部真菌感染临床实践专家共识(2022版)[J]. 中华儿科志, 2022, 60(4):274-282. |
[5] |
LEE J, NG P, HAMANDI B, et al. Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review[J]. Ann Pharmacother, 2021, 55(4):509-529. doi: 10.1177/1060028020948174 |
[6] |
陈恳, 张相林, 克晓燕, 等. 《伏立康唑个体化用药指南》解读[J]. 临床药物治疗杂志, 2019, 17(3):47-52,78. doi: 10.3969/j.issn.1672-3384.2019.03.012 |
[7] |
中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31(4):355-384. doi: 10.3760/cma.j.cn501113-20230419-00176-1 |
[8] |
CHEN K, ZHANG X L, KE X Y, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society[J]. Ther Drug Monit, 2018, 40(6):663-674. doi: 10.1097/FTD.0000000000000561 |
[9] |
PATTERSON T F, THOMPSON G R, DENNING D W, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4):e1-e60. |
[10] |
MORIYAMA B, OBENG A O, BARBARINO J, et al. Clinical pharmacogenetics implementation consortium(CPIC)guidelines for CYP2C19 and voriconazole therapy[J]. Clin Pharmacol Ther, 2017, 102(1):45-51. |
[11] |
TAHER KW, ALMOFADA R, ALOMAIR S, et al. Therapeutic drug monitoring of voriconazole in critically Ill pediatric patients: a single-center retrospective study. Paediatr Drugs, 2024, 26(2): 197-203. |
[12] |
PASCUAL A, CSAJKA C, BUCLIN T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections[J]. Clin Infect Dis, 2012, 55(3):381-390. doi: 10.1093/cid/cis437 |
[13] |
郭一萌, 安琳娜, 陈恳, 等. 伏立康唑在不同年龄段使用中安全性和有效性以及药代动力学差异的系统评价[J]. 中国临床药理学杂志, 2016, 32(3):261-263. |
[14] |
BAHAR MA, SETIAWAN D, HAK E, et al. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6[J]. Pharmacogenomics, 2017, 18(7):701-739. doi: 10.2217/pgs-2017-0194 |
[15] |
SHI C C, XIAO Y B, MAO Y, et al. Voriconazole: a review of population pharmacokinetic analyses[J]. Clin Pharmacokinet, 2019, 58(6):687-703. |
[16] |
邵贝贝, 赵宁民, 段虹飞, 等. 基于基因多态性的伏立康唑药代动力学研究状况[J]. 中国临床药理学杂志, 2016, 32(7):663-666. |
[17] |
FAN X, ZHANG H, WEN Z, et al. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients. Pharmacogenet Genomics[J]. 2022, 32(4): 152-158. |
[18] |
AIUCHI N, NAKAGAWA J, SAKURABA H, et al. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole[J]. Pharmacol Res Perspect, 2022, 10(2):e00935. doi: 10.1002/prp2.935 |